Lutetium PSMA Therapy Cost in India: An Overview

What is Lutetium PSMA Therapy?

Lutetium PSMA therapy is an advanced treatment for prostate cancer that exploits the prostate-specific membrane antigen (PSMA) expressed on the surface of cancer cells. The therapy uses PSMA ligands, such as PSMA-DKFZ-617, radiolabeled with therapeutic radioisotopes like Lu-177 (a beta emitter) or Ac225 (an alpha emitter). These radioisotopes deliver high-dose targeted radiation directly to tumor sites, a process known as radioligand therapy (RLT).

Lutetium PSMA Therapy Cost in India: An Overview

How Does It Work?

The therapeutic molecule binds specifically to PSMA on tumor cells. Once injected, the therapy substance travels through the bloodstream, accumulating in the tumor tissue. This results in targeted irradiation of the malignant cells, while normal tissue experiences minimal radiation exposure, extending only a few millimeters.

Benefits and Efficacy

Clinical studies indicate that RLT effectively reduces tumor growth or significantly decreases tumor volume in most advanced cases. Benefits include pain reduction, lower PSA levels, and improved quality of life. For the therapy to be effective, the tumor must express PSMA receptors, which can be confirmed via a Ga68 PSMA PET CT scan.

Treatment Protocol

Typically, 3-4 doses of Lu177 PSMA therapy are administered at intervals of 6-8 weeks. The injection process takes about 10 minutes, followed by intravenous hydration. The entire procedure is conducted as a short daycare admission. Dosimetry scans are performed for up to 4 days post-procedure, requiring a 5-day stay in Delhi for each treatment cycle.

Safety and Tolerance

Lu177 PSMA therapy is well-tolerated with minimal side effects. Some patients may experience fatigue immediately post-infusion, nausea, and loss of appetite during the first week. A slight reduction in red blood cells may occur after a few weeks, typically resolving without additional treatment.

Effectiveness and Duration

Approximately 75-80% of patients experience a reduction in tumor size and PSA levels, with the response duration averaging around one year. Some patients may maintain a positive response for a longer period. In cases of relapse after an initial good response, the therapy can be repeated or switched to the more potent yet slightly more toxic Ac225 PSMA therapy.

Top Hospitals for Lutetium PSMA Therapy in India

Here are some top hospitals in India offering Lutetium PSMA Therapy for prostate cancer treatment:

1. Fortis Memorial Research Institute, Gurgaon: Offers advanced diagnostic and therapeutic options for prostate cancer, including PSMA therapy.

2. Medanta – The Medicity, Gurgaon: Provides comprehensive cancer care with advanced treatment options like Lutetium PSMA Therapy.

3. Apollo Hospitals, Chennai: This hospital provides state-of-the-art cancer treatment, including Lutetium PSMA Therapy, with a team of experienced oncologists.

These hospitals are equipped with modern technology and have experienced medical professionals to provide advanced cancer treatments, including Lutetium PSMA Therapy.

Cost of Lutetium PSMA Therapy in India

Each dose of Lutetium PSMA therapy costs around USD 6000. This cost includes the non-carrier-added Lu177 sourced from ITM Germany, approved by both European and Indian pharmacopoeia.

Conclusion

Lutetium PSMA therapy represents a promising treatment option for prostate cancer patients in India, offering targeted radiation therapy with a favorable safety profile. Its effectiveness in reducing tumor size and improving quality of life, combined with its relatively manageable side effects, makes it a valuable option for eligible patients.

FAQs about Lutetium PSMA Therapy

Lutetium PSMA therapy is an advanced treatment for prostate cancer that targets the prostate-specific membrane antigen (PSMA) expressed on cancer cells. It uses a radiolabeled PSMA ligand, such as Lutetium-177, to deliver high-dose targeted radiation directly to tumor sites, effectively reducing tumor size and PSA levels.
The therapy involves 3-4 doses administered at intervals of 6-8 weeks. Each injection takes about 10 minutes, followed by intravenous hydration. The entire process is conducted as a short daycare admission, with dosimetry scans performed for up to 4 days post-procedure, requiring a 5-day stay in Delhi for each treatment cycle.
Lutetium PSMA therapy is generally well-tolerated. Some patients may experience immediate post-infusion fatigue, nausea, and loss of appetite during the first week. A slight reduction in red blood cells may occur after a few weeks, but this typically resolves without additional treatment.
Each dose of Lutetium PSMA therapy costs approximately USD 6000. This includes the non-carrier-added Lutetium-177 sourced from ITM Germany, which is approved by both the European and Indian pharmacopoeia.

Top Doctors for this Procedure

Doctors and Surgeons on our panel are renowned and highly experienced.

Need assistance for choosing the best doctor for your medical problem?

    Top Hospitals